Removing more tissue during a partial mastectomy could spare thousands of breast cancer patients a second surgery, according to a Yale Cancer Center study. —> Read More
Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a researcher who co-led PERSIST-1, the worldwide phase 3 clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent. —> Read More
A new phase 3 study in some of the most difficult-to-treat patients, women with endocrine-resistant disease, showed that the newly approved drug, palbociclib, more than doubled the time to cancer recurrence for women with hormone-receptor (HR+) positive metastatic breast cancer. —> Read More
ESMO, the European Society for Medical Oncology, has announced the publication of the ESMO Magnitude of Clinical Benefit Scale, a tool to assist oncology clinicians in evaluating the most effective anti-cancer medicines for their patients. —> Read More
“Those ‘inactive’ spores we sent you? Guess what?”
– This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.
America is cracking down on unhealthy trans fats in food. It’s a welcome move that should spark a rethink in unregulated countries, says Oliver Tickell (full text available to subscribers)
Researchers will be attempting to locate the remains of the famed aviator’s aircraft next month. When Amelia Earhart disappeared over the Pacific Ocea… —> Read More
This parachute testing for NASA’s InSight mission to Mars was conducted inside the world’s largest wind tunnel, at NASA Ames Research Center, Moffett Field, California, in February 2015.
Academic studies can be fascinating… and totally confusing. So we decided to strip away all of the scientific jargon and break them down for you.
It’s been found that people determine whether or not they’re attracted to someone within 100 milliseconds of an initial sighting. First impressions can be critical, especially now that we can swipe away potential dates on online dating apps as quickly as our brains reject them. Physical attractiveness is certainly a factor — previous research has identified a “halo effect,” whereby we assign additional positive traits to attractive people, as well as a “devil effect” that might prompt us to assume that unattractive people have other “bad” characteristics. These effects are also seen when someone violates social norms, either in a harmless or creepy way. But to what degree do these halo and devil biases affect our open-mindedness to strangers? Could there be implications to our dating lives — which rely more and more on digital first impressions, with only a photo and a few discernible characteristics to go by?
In a recent study, researchers from Eastern Kentucky University brought in 170 female college students to see how physical attractiveness affected how they reacted to men in normal vs. lab-designed creepy situations. They presented the female students with two different hypothetical scenarios: The first scenario involved a male stranger who asks to borrow a pen in class, and the second involved a male stranger who approaches the female to ask to take her photograph for a modeling project. (Can you guess which scenario was supposed to be the creepy one?)
The women were divided into two groups and shown photos of two men, one deemed attractive and one deemed unattractive by the researchers. One group received —> Read More
Removing more tissue during a partial mastectomy could spare thousands of breast cancer patients a second surgery, according to a Yale Cancer Center study. The findings were published online May 30 in the New England Journal of Medicine and presented at the 2015 Annual Meeting of the American Society of Clinical Oncology in Chicago. —> Read More